Hexavalent DNL Antibody Constructs for B-Cell Lymphoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies using monoclonal antibodies face challenges with immunogenicity and suboptimal pharmacokinetics, and combination therapies involving multiple antibodies can be costly and inconvenient, while existing methods for producing bispecific antibodies are complex and inefficient.
Innovation Solution
The development of hexavalent dock-and-lock (DNL) constructs using antibodies or antibody fragments that bind to CD20 and/or CD22, employing a specific binding interaction between dimerization and docking domains and anchor domains to create stable, multivalent complexes with enhanced affinity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapies involving multiple antibodies are used to enhance anti-tumor activity, then therapeutic efficacy is improved, but treatment cost and operational complexity increase
Solution Approach 1:
The patent combines multiple antibody specificities into a single hexavalent DNL construct that can simultaneously bind to both CD20 and CD22 antigens. This merging approach achieves the therapeutic benefits of combination therapy while reducing treatment complexity by administering a single agent instead of multiple separate antibodies
Solution Approach 2:
The hexavalent DNL construct serves multiple functions simultaneously: it binds to two different antigens (CD20 and CD22), recruits complement proteins, and induces antibody-dependent cellular cytotoxicity. This multi-functionality allows one agent to replace what would traditionally require multiple separate therapeutic agents
2Adaptability or versatility
If existing methods for producing bispecific antibodies are used, then dual-specificity is achieved, but production complexity and inefficiency increase
Solution Approach 1:
The DNL construct is divided into distinct functional modules: a dimerization and docking domain (DDD) that mediates self-assembly, and anchor domains (AD) that bind to Fc regions of antibodies. This segmentation allows for modular assembly and simplified production compared to traditional bispecific antibody methods
Solution Approach 2:
The hexavalent DNL construct utilizes self-assembly through the DDD domain that spontaneously dimerizes and docks with AD domains. This self-service mechanism eliminates the need for complex chemical crosslinking or enzymatic ligation steps, significantly simplifying the manufacturing process
3Ease of manufacture
If monovalent antibodies are used for treatment, then production is simple, but pharmacokinetic properties and therapeutic efficacy are suboptimal
Solution Approach 1:
The patent merges multiple antibody binding sites into a single hexavalent construct, achieving multivalency that enhances pharmacokinetic properties including extended circulation half-life and improved target cell binding avidity, while maintaining production simplicity through the self-assembly mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hexavalent DNL constructs demonstrate improved pharmacokinetic properties and enhanced anti-lymphoma activity with reduced toxicity, achieving potent antiproliferative effects and apoptosis in B-cell lymphoma and leukemia cells, while maintaining stability and retaining the binding specificity of parent antibodies.
Implementation Method 1
The DNL technique takes advantage of the specific, high-affinity binding interaction between a dimerization and docking domain (DDD) sequence from the regulatory subunit of human cAMP-dependent protein kinase (PKA), such as human PKA RIα, RIβ, RIIα or RIIβ, and an anchor domain (AD) sequence from any of a variety of AKAP proteins
Implementation Method 2
the antibodies or fragments thereof bind to CD20 and/or CD22... exhibit enhanced toxicity to CD20 and/or CD22 expressing target cells, by inducing multiple signaling pathways in the target cell
Data Source
AI summary
Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKKα/β and IκBα, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.